Literature DB >> 12598520

Promiscuous coupling at receptor-Galpha fusion proteins. The receptor of one covalent complex interacts with the alpha-subunit of another.

Paola Molinari1, Caterina Ambrosio, Daniela Riitano, Maria Sbraccia, Maria Cristina Grò, Tommaso Costa.   

Abstract

Fusion proteins between heptahelical receptors (GPCR) and G protein alpha-subunits show enhanced signaling efficiency in transfected cells. This is believed to be the result of molecular proximity, because the interaction between linked modules of one protein chain, if not constrained by structure, should be strongly favored compared with the same in which partners react as free species. To test this assumption we made a series of fusion proteins (type 1 and 4 opioid receptors with G(o) and beta(2) adrenergic and dopamine 1 receptors with G(sL)) and some mutated analogs carrying different tags and defective GPCR or Galpha subunits. Using cotransfection experiments with readout protocols able to distinguish activation at fused and non-fused alpha-subunits, we found that both the GPCR and the Galpha limb of one fusion protein can freely interact with non-fused proteins and the tethered partners of a neighboring fusion complex. Moreover, a bulky polyanionic inhibitor can suppress with identical potency receptor-Galpha interaction, either when occurring between latched domains of a fused system or separate elements of distinct molecules, indicating that the binding surfaces are equally accessible in both cases. These data demonstrate that there is no entropy drive from the linked condition of fusion proteins and suggest that their signaling may result from the GPCR of one complex interacting with the alpha-subunit of another. Moreover, the enhanced coupling efficiency commonly observed for fusion proteins is not due to the receptor tether, but to the transmembrane helix that anchors Galpha to the membrane.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598520     DOI: 10.1074/jbc.M300731200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Coupling of beta2-adrenoceptors to XLalphas and Galphas: a new insight into ligand-induced G protein activation.

Authors:  A I Kaya; O Ugur; S S Oner; M Bastepe; H O Onaran
Journal:  J Pharmacol Exp Ther       Date:  2009-01-14       Impact factor: 4.030

2.  Smoothened is a fully competent activator of the heterotrimeric G protein G(i).

Authors:  Feng Shen; Lan Cheng; Andrew E Douglas; Natalia A Riobo; David R Manning
Journal:  Mol Pharmacol       Date:  2013-01-04       Impact factor: 4.436

Review 3.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  Morphine-like opiates selectively antagonize receptor-arrestin interactions.

Authors:  Paola Molinari; Vanessa Vezzi; Maria Sbraccia; Cristina Grò; Daniela Riitano; Caterina Ambrosio; Ida Casella; Tommaso Costa
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

5.  Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR).

Authors:  Ryan T Strachan; Jin-peng Sun; David H Rominger; Jonathan D Violin; Seungkirl Ahn; Alex Rojas Bie Thomsen; Xiao Zhu; Andrew Kleist; Tommaso Costa; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2014-03-25       Impact factor: 5.157

6.  Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.

Authors:  Yang Han; Irina S Moreira; Eneko Urizar; Harel Weinstein; Jonathan A Javitch
Journal:  Nat Chem Biol       Date:  2009-08-02       Impact factor: 15.040

7.  Delayed internalization and lack of recycling in a beta2-adrenergic receptor fused to the G protein alpha-subunit.

Authors:  Maria Grazia Di Certo; Enrico M Batassa; Ida Casella; Annalucia Serafino; Aristide Floridi; Claudio Passananti; Paola Molinari; Elisabetta Mattei
Journal:  BMC Cell Biol       Date:  2008-10-07       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.